NorthCoast Asset Management’s Myriad Genetics MYGN Stock Holding History

NorthCoast Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-65,256	Closed	-$2M	–	191
2016 Q2	$2M	Buy	+65,256	New	+$2.27M	0.14%	83
2015 Q1	–	Sell	-73,616	Closed	-$2.51M	–	167
2014 Q4	$2.51M	Sell	73,616 -6,860	-9%	-$243K	0.12%	91
2014 Q3	$3.1M	Buy	80,476 +8,698	+12%	+$325K	0.15%	77
2014 Q2	$2.79M	Buy	71,778 +202	+0.3%	+$7.52K	0.16%	79
2014 Q1	$2.45M	Sell	71,576 -22,890	-24%	-$709K	0.16%	77
2013 Q4	$1.98M	Sell	94,466 -30,475	-24%	-$771K	0.13%	86
2013 Q3	$2.94M	Buy	+124,941	New	+$3.55M	0.2%	38

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NorthCoast Asset Management's MYGN Position: Q3 2016 in Review

NorthCoast Asset Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 65,256 shares — an estimated $2M sold.

NorthCoast Asset Management first reported a position in MYGN in Q3 2013 and held it in 7 quarters. The position peaked at $3.1M in Q3 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

NorthCoast Asset Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
NorthCoast Asset Management sold 65,256 Myriad Genetics shares in Q3 2016, an estimated $2M.
NorthCoast Asset Management first reported a position in Myriad Genetics in Q3 2013 and held it in 7 quarters.
NorthCoast Asset Management's Myriad Genetics position peaked at $3.1M in Q3 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on NorthCoast Asset Management's 13F filing for Q3 2016, filed 9 Nov 2016.